News

31/08/2015

Ares Allergy Holdings Plc has secures AMF approval of its prospectus for listing its shares on Euronext Paris

22/07/15
Half-year sales: Strong revenue growth in H1 2015 (up 8.7%) exceeding targets

> Read more

[more]
08/06/15
Stallergenes is pleased to see the mobile allergen exposure chamber at the 2015 EAACI congress, Barcelona

> Read more

[more]

Follow us on :

STALLERGENES, A GLOBAL ALLERGY PLAYER


Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. 

Stallergenes’ comprehensive approach to allergic diseases includes a complete portfolio combining diagnosis products and treatments and a new generation of allergen immunotherapy treatments.